“The first half of 2025 has been transformative for I-Mab (IMAB),” said Sean Fu, PhD, Chief Executive Officer of I-Mab. “Our presentation at ESMO GI showcased compelling Phase 1b combination data for givastomig, reinforcing our confidence in its potential to be a best-in-class Claudin 18.2-directed therapy for metastatic gastric cancers in the 1L setting. Thanks to strong study momentum and active investigator engagement, we completed enrollment of the planned Phase 1b dose expansion cohorts ahead of schedule and expect to report topline data in Q1 2026. We believe our strong cash position and unwavering focus on value creation, position I-Mab to deliver meaningful clinical data and improve the lives of patients.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMAB:
- I MAB (ADS) options imply 11.8% move in share price post-earnings
- I-Mab Completes Enrollment in Phase 1b Study for Givastomig in Gastric Cancer
- I-Mab completes enrollment in Phase 1b dose expansion study for givastomig
- 3 Penny Stocks to Watch Now, 8/5/25
- I-Mab Announces $65 Million ADS Offering to Advance Cancer Treatment Pipeline